Use baseline axial length measurements in myopic patients to predict the control of myopia with and without atropine 0.01.

<h4>Purpose</h4>Identifying axial length growth rate as an indicator of fast progression before initiating atropine 0.01% for myopia progression in children.<h4>Method</h4>From baseline, axial length growth over six months was measured prospectively. Subjects were then initia...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Loreto V T Rose, Angela M Schulz, Stuart L Graham
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/44d663cff92047a89290a806dcb7a59a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:44d663cff92047a89290a806dcb7a59a
record_format	dspace
spelling	oai:doaj.org-article:44d663cff92047a89290a806dcb7a59a2021-12-02T20:06:58ZUse baseline axial length measurements in myopic patients to predict the control of myopia with and without atropine 0.01.1932-620310.1371/journal.pone.0254061https://doaj.org/article/44d663cff92047a89290a806dcb7a59a2021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0254061https://doaj.org/toc/1932-6203<h4>Purpose</h4>Identifying axial length growth rate as an indicator of fast progression before initiating atropine 0.01% for myopia progression in children.<h4>Method</h4>From baseline, axial length growth over six months was measured prospectively. Subjects were then initiated on atropine 0.01% if axial length growth was greater than 0.1mm per 6 months (fast progressors), axial length and spherical equivalent change measurements recorded every six months. The rate of change was compared to the baseline pre-treatment rate. If axial length change was below the threshold, subjects received monitoring only.<h4>Results</h4>73 subjects were identified as fast progressors and commenced atropine 0.01%, (mean baseline refraction of OD -2.9±1.6, OS -2.9±1.8 and a mean baseline axial length OD 24.62 ± 1.00 mm, OS 24.53 ± 0.99 mm). At six months, the mean paired difference of axial length growth rate was significantly reduced by 50% of baseline (all 73 subjects, p<0.05). 53 subjects followed to 12 months, and 12 to 24 months maintained a reduced growth rate. Change in mean spherical equivalent was significantly reduced compared to pre-treatment refractive error (mean paired difference p<0.05) and at each subsequent visit. 91 children were slow progressors and remained untreated. Their axial length growth rate did not change significantly out to 24 months. Spherical equivalent changed less than -0.5D annually in this group.<h4>Conclusion</h4>Identifying fast progressors before treatment initiation demonstrated a strong treatment effect with atropine 0.01% reducing their individual rate of myopia progression by 50%. Another large group of myopic children, slow progressors, continued without medical intervention. A baseline axial length growth rate is proposed as a guideline to identify fast progressors who are more likely to benefit from atropine 0.01%.Loreto V T RoseAngela M SchulzStuart L GrahamPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 7, p e0254061 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Loreto V T Rose Angela M Schulz Stuart L Graham Use baseline axial length measurements in myopic patients to predict the control of myopia with and without atropine 0.01.
description	<h4>Purpose</h4>Identifying axial length growth rate as an indicator of fast progression before initiating atropine 0.01% for myopia progression in children.<h4>Method</h4>From baseline, axial length growth over six months was measured prospectively. Subjects were then initiated on atropine 0.01% if axial length growth was greater than 0.1mm per 6 months (fast progressors), axial length and spherical equivalent change measurements recorded every six months. The rate of change was compared to the baseline pre-treatment rate. If axial length change was below the threshold, subjects received monitoring only.<h4>Results</h4>73 subjects were identified as fast progressors and commenced atropine 0.01%, (mean baseline refraction of OD -2.9±1.6, OS -2.9±1.8 and a mean baseline axial length OD 24.62 ± 1.00 mm, OS 24.53 ± 0.99 mm). At six months, the mean paired difference of axial length growth rate was significantly reduced by 50% of baseline (all 73 subjects, p<0.05). 53 subjects followed to 12 months, and 12 to 24 months maintained a reduced growth rate. Change in mean spherical equivalent was significantly reduced compared to pre-treatment refractive error (mean paired difference p<0.05) and at each subsequent visit. 91 children were slow progressors and remained untreated. Their axial length growth rate did not change significantly out to 24 months. Spherical equivalent changed less than -0.5D annually in this group.<h4>Conclusion</h4>Identifying fast progressors before treatment initiation demonstrated a strong treatment effect with atropine 0.01% reducing their individual rate of myopia progression by 50%. Another large group of myopic children, slow progressors, continued without medical intervention. A baseline axial length growth rate is proposed as a guideline to identify fast progressors who are more likely to benefit from atropine 0.01%.
format	article
author	Loreto V T Rose Angela M Schulz Stuart L Graham
author_facet	Loreto V T Rose Angela M Schulz Stuart L Graham
author_sort	Loreto V T Rose
title	Use baseline axial length measurements in myopic patients to predict the control of myopia with and without atropine 0.01.
title_short	Use baseline axial length measurements in myopic patients to predict the control of myopia with and without atropine 0.01.
title_full	Use baseline axial length measurements in myopic patients to predict the control of myopia with and without atropine 0.01.
title_fullStr	Use baseline axial length measurements in myopic patients to predict the control of myopia with and without atropine 0.01.
title_full_unstemmed	Use baseline axial length measurements in myopic patients to predict the control of myopia with and without atropine 0.01.
title_sort	use baseline axial length measurements in myopic patients to predict the control of myopia with and without atropine 0.01.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/44d663cff92047a89290a806dcb7a59a
work_keys_str_mv	AT loretovtrose usebaselineaxiallengthmeasurementsinmyopicpatientstopredictthecontrolofmyopiawithandwithoutatropine001 AT angelamschulz usebaselineaxiallengthmeasurementsinmyopicpatientstopredictthecontrolofmyopiawithandwithoutatropine001 AT stuartlgraham usebaselineaxiallengthmeasurementsinmyopicpatientstopredictthecontrolofmyopiawithandwithoutatropine001
_version_	1718375299070033920

Use baseline axial length measurements in myopic patients to predict the control of myopia with and without atropine 0.01.

Ejemplares similares